Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies

Overview

Journal Vaccines (Basel)

Date 2024 Nov 26

PMID 39591123

Authors

Palaniyandi Muthukutty

Jaime MacDonald

So Young Yoo

Affiliations

Soon will be listed here.

Abstract

Emerging viral diseases, including seasonal illnesses and pandemics, pose significant global public health risks. Respiratory viruses, particularly coronaviruses and influenza viruses, are associated with high morbidity and mortality, imposing substantial socioeconomic burdens. This review focuses on the current landscape of respiratory viruses, particularly influenza and SARS-CoV-2, and their antiviral treatments. It also discusses the potential for pandemics and the development of new antiviral vaccines and therapies, drawing lessons from past outbreaks to inform future strategies for managing viral threats.

Citing Articles

Advances and Challenges in Antiviral Development for Respiratory Viruses.

De Jesus-Gonzalez L, Leon-Juarez M, Lira-Hernandez F, Rivas-Santiago B, Velazquez-Cervantes M, Mendez-Delgado I Pathogens. 2025; 14(1).

PMID: 39860981 PMC: 11768830. DOI: 10.3390/pathogens14010020.

References

Kalil A, Thomas P . Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care. 2019; 23(1):258. PMC: 6642581. DOI: 10.1186/s13054-019-2539-x. View

Nguyen H, Nguyen H, Lan P, Thai N, Sikora M, Li M . Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. Chem Soc Rev. 2023; 52(18):6497-6553. DOI: 10.1039/d1cs01170g. View

Chandwani A, Shuter J . Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2009; 4(5):1023-33. PMC: 2621403. DOI: 10.2147/tcrm.s3285. View

Memoli M, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K . The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2013; 58(2):214-24. PMC: 3871797. DOI: 10.1093/cid/cit725. View

de Vries M, Mohamed A, Prescott R, Valero-Jimenez A, Desvignes L, OConnor R . A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL inhibitor PF-00835231 as a potential new treatment for COVID-19. J Virol. 2021; 95(7). PMC: 8139662. DOI: 10.1128/JVI.01819-20. View

Hui K, Cheung M, Perera R, Ng K, Bui C, Ho J . Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med. 2020; 8(7):687-695. PMC: 7252187. DOI: 10.1016/S2213-2600(20)30193-4. View

Ruiz-Aravena M, McKee C, Gamble A, Lunn T, Morris A, Snedden C . Ecology, evolution and spillover of coronaviruses from bats. Nat Rev Microbiol. 2021; 20(5):299-314. PMC: 8603903. DOI: 10.1038/s41579-021-00652-2. View

Lamb Y . BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021; 81(4):495-501. PMC: 7938284. DOI: 10.1007/s40265-021-01480-7. View

Syed Y . Ensitrelvir Fumaric Acid: First Approval. Drugs. 2024; 84(6):721-728. DOI: 10.1007/s40265-024-02039-y. View

10.

Wynia M, Beaty L, Bennett T, Carlson N, Davis C, Kwan B . Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest. 2022; 163(5):1061-1070. PMC: 9613796. DOI: 10.1016/j.chest.2022.10.020. View

11.

Wilson-Welder J, Torres M, Kipper M, Mallapragada S, Wannemuehler M, Narasimhan B . Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. 2008; 98(4):1278-316. PMC: 8092333. DOI: 10.1002/jps.21523. View

12.

Excler J, Saville M, Berkley S, Kim J . Vaccine development for emerging infectious diseases. Nat Med. 2021; 27(4):591-600. DOI: 10.1038/s41591-021-01301-0. View

13.

Subbarao K, Mahanty S . Respiratory Virus Infections: Understanding COVID-19. Immunity. 2020; 52(6):905-909. PMC: 7237932. DOI: 10.1016/j.immuni.2020.05.004. View

14.

Harrington W, Kackos C, Webby R . The evolution and future of influenza pandemic preparedness. Exp Mol Med. 2021; 53(5):737-749. PMC: 8099712. DOI: 10.1038/s12276-021-00603-0. View

15.

Sabbaghi A, Miri S, Keshavarz M, Zargar M, Ghaemi A . Inactivation methods for whole influenza vaccine production. Rev Med Virol. 2019; 29(6):e2074. DOI: 10.1002/rmv.2074. View

16.

Patel R, Kaki M, Potluri V, Kahar P, Khanna D . A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022; 18(1):2002083. PMC: 8862159. DOI: 10.1080/21645515.2021.2002083. View

17.

Davidson S, Crotta S, McCabe T, Wack A . Pathogenic potential of interferon αβ in acute influenza infection. Nat Commun. 2014; 5:3864. PMC: 4033792. DOI: 10.1038/ncomms4864. View

18.

Kutti-Sridharan G, Vegunta R, Vegunta R, Mohan B, Rokkam V . SARS-CoV2 in Different Body Fluids, Risks of Transmission, and Preventing COVID-19: A Comprehensive Evidence-Based Review. Int J Prev Med. 2020; 11:97. PMC: 7518359. DOI: 10.4103/ijpvm.IJPVM_255_20. View

19.

Dayan G, Rouphael N, Walsh S, Chen A, Grunenberg N, Allen M . Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. Lancet Respir Med. 2023; 11(11):975-990. PMC: 10872639. DOI: 10.1016/S2213-2600(23)00263-1. View

20.

Vikkurthi R, Ansari A, Pai A, Jha S, Sachan S, Pandit S . Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Nat Microbiol. 2022; 7(7):974-985. DOI: 10.1038/s41564-022-01161-5. View